drugset / Trial / NCT06293950

Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism

NCT06293950 ↗

Phase 1 Recruiting 14 enrolled University of Jordan
NaSingle-groupOpen-labelTreatment

Summary

Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.

Timeline

Start
2022-03-09
Primary completion
2026-06
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Wharton Jelly Mesenchymal Stromal Cell Unknown 1e+06 cells/kg Intravenous

Indications